-
Specialties
Board Certification
American Board of Internal Medicine (Internal Medicine)American Board of Internal Medicine (Sub: Hematology)American Board of Internal Medicine (Sub: Medical Oncology)Patient Rating
4.9 /5The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.
The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient Comments
Patient comments are gathered from our patient experience survey and displayed in their entirety.
Patients are de-identified for confidentiality and patient privacy.August 06, 2022Dr. Ward has been my Oncologist since February, 2017. He is an amazing dr and human being! He has always shown me respect for my decisions and concern. I am so grateful that I had him, Rosie and his staff to assist me through the journey!
July 18, 2022Very good
July 08, 2022The doctor takes his time to communicate about my progress and my treatment. And shows genuine care.
July 08, 2022I have loved my experience with Dr. Ward, Rosie, and Allison. It was the best care in such a not so fun situation. I will always think highly of the Hunstmans because of these three special and caring people. Every step of every treatment was explained.
May 05, 2022Dr Ward was very thorough and considerate.
April 30, 2022Excellent unhurried exam and conversation as usual.
April 15, 2022Great
April 02, 2022Good experience
March 15, 2022DrWard is a kind and compassionate Dr. I couldn't see myself with any other Dr on this journey!
-
Board Certification and Academic Information
Academic Departments Internal Medicine -Primary Academic Divisions Oncology
Board Certification American Board of Internal Medicine (Internal Medicine)American Board of Internal Medicine (Sub: Hematology)American Board of Internal Medicine (Sub: Medical Oncology)Education history
Fellowship Hematology/Oncology - University of Utah School of Medicine Fellow Internal Medicine - Duke University Medical Center Resident Internship Internal Medicine - Duke University Medical Center Intern Medicine - University of Utah Hospital School of Medicine M.D. Undergraduate University of Utah B.S. Selected Publications
Journal Article
- Mooney K, Titchener K, Haaland B, Coombs LA, ONeil B, Nelson R, McPherson JP, Kirchhoff AC, Beck AC, Ward JH (2021). Evaluation of Oncology Hospital at Home: Unplanned Health Care Utilization and Costs in the Huntsman at Home Real-World Trial. J Clin Oncol, 39(23), JCO2003609.
- Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami PJ (2021). A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer, 21(1), 510.
- Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Matro J, Mayer IA, Mortimer J, ORegan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns JL, Kumar R (2021). NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. J Natl Compr Canc Netw, 19(5), 484-493.
- Riedel RF, Ballman KV, Lu Y, Attia S, Loggers ET, Ganjoo KN, Livingston MB, Chow W, Wright J, Ward JH, Rushing D, Okuno SH, Reed DR, Liebner DA, Keedy VL, Mascarenhas L, Davis LE, Ryan C, Reinke DK, Maki RG (2020). A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study. Oncologist, 25(11), e1655-e1662.
- Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Krishnamurthy J, Lyons J, Marcom PK, Matro J, Mayer IA, Moran MS, Mortimer J, ORegan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Young JS, Burns JL, Kumar R (2020). Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 18(4), 452-478.
- Goetz MP, Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Farrar WB, Giordano SH, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, Moran MS, Mortimer J, ORegan RM, Patel SA, Pierce LJ, Reed EC, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Telli ML, Ward JH, Young JS, Shead DA, Kumar R (2019). NCCN Guidelines Insights: Breast Cancer, Version 3.2018. J Natl Compr Canc Netw, 17(2), 118-126.
- Katz BJ, Ward JH, Digre KB, Creel DJ, Mamalis N (2003). Persistent severe visual and electroretinographic abnormalities after intravenous Cisplatin therapy. J Neuroophthalmol, 23(2), 132-5.
- Bachman TR, Sawitzke AD, Perkins SL, Ward JH, Cannon GW (1996). Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases. Arthritis Rheum, 39(2), 325-9.
- Mann H, Ward JH, Samlowski WE (1990). Vascular leak syndrome associated with interleukin-2: chest radiographic manifestations. Radiology, 176(1), 191-4.
Abstract
- Yousef Zakharia, Olivier Rixe, John Harris Ward, Joseph J Drabick, Montaser F Shaheen, Mohammed M Milhem, David Munn, Eugene Paul Kennedy, Nicholas N Vahanian, Charles J Link, Robert R McWilliams, University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Iowa City, IA, GRU Cancer Center, Augusta, GA, Huntsman Cancer Inst Univ of Utah, Salt Lake City, UT, Penn State Hershey Medical Center, Hershey, PA, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, Georgia Cancer Center, Augusta University, Augusta, GA, NewLink Genetics Corporation, Ames, IA, Mayo Clinic, Rochester, MN (06/04/2018). Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma.Presented at 2018 ASCO Annual meeting June 4, 2018. [Abstract]. J Clin Oncology, 36(suppl. abstr 9512).
-
News & Podcasts
Huntsman Cancer Institute News